Arthritis is identified as an independent risk factor for prostate cancer, with significant associations found in various analyses. The study utilized NHANES data and Mendelian randomization to ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that patients won't see these ...

Prostate cancer remains one of the most significant health concerns for men worldwide, with detection and treatment options constantly evolving. Understanding this common condition can literally ...

Among male relatives of women with primary ovarian insufficiency, risks for prostate cancer, non-obstructive azoospermia, and severe oligozoospermia were elevated. Non-obstructive azoospermia (NOA ...

Prostate cancer that has spread to other parts of the body has limited treatment options, but a biomedical research group affiliated with Main Line Health has begun investigating a new therapy for ...

prostate, head and neck and gastrointestinal cancers at Ochsner MD Anderson Cancer Center. Most recently, Russell has worked to bring Pluvicto to Baton Rouge — a federal Food and Drug ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively ...

Share on Pinterest Skipping cancer screenings may contribute to a higher mortality rate from prostate cancer, new research suggests. jamesbenet/Getty Images Men who often miss their prostate ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...